Mark Markowski, MD, PhD | Authors

Articles

Sabizabulin for the Treatment of Men With mCRPC

June 17, 2022

Mark Markowski, MD, PhD, discusses the design of a phase 1B/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who have had treatment and progression on an androgen receptor–targeting agent.